Stockscreener 앱 받기
0.7478
1.49%
0.011
전일 마감가:
$0.7368
열려 있는:
$0.7504
하루 거래량:
43,136
Relative Volume:
0.32
시가총액:
$13.90M
수익:
$420.00K
순이익/손실:
$-19.65M
주가수익비율:
-0.00541
EPS:
-138.243
순현금흐름:
$-26.08M
1주 성능:
-1.07%
1개월 성능:
-50.48%
6개월 성능:
-96.60%
1년 성능:
-99.79%
1일 변동 폭
$0.72
$0.777
1주일 범위
$0.6951
$0.88
52주 변동 폭
$0.59
$1,030.00
칼라 파마슈티컬스 Stock (KALA) Company Profile
명칭
Kala Bio Inc
전화
781-996-5252
주소
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.7478 | 12.47M | 420.00K | -19.65M | -26.08M | -138.24 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
칼라 파마슈티컬스 Stock (KALA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-09-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | 개시 | Mizuho | Outperform |
| 2025-07-11 | 개시 | Ladenburg Thalmann | Buy |
| 2022-03-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-09-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-07-23 | 개시 | Northland Capital | Outperform |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-27 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-09 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 개시 | Jefferies | Buy |
모두보기
칼라 파마슈티컬스 주식(KALA)의 최신 뉴스
KALA BIO Inc (KALA) Institutional Confidence - TradingKey
KALA BIO Inc (KALA) Cash Flow - TradingKey
KALA BIO Inc (KALA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KALA BIO Inc (KALA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
KALA BIO Inc (KALA) Balance Sheet - TradingKey
KALA|KALA BIO Inc|Price:0.671|Chg%:+0.036 - TradingKey
KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark - Stocktwits
KALA BIO, Inc. Revenue Breakdown – NASDAQ:KALA - TradingView
KALA|KALA BIO Inc|Price:0.634|Chg%:+0.024 - TradingKey
KALA BIO Inc (KALA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kala Bio, Inc. Files Form 8-K with SEC Detailing Nasdaq Listing and Corporate Information - Minichart
KALA BIO Inc (KALA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kala Bio Files ATM Offering Of Up To $250 Million In Common StockSEC Filing - TradingView
Frontier tech research, news & data - MLQ.ai
Kala Bio announces 1-for-50 reverse stock split effective Friday - Investing.com
Form 13D/A KALA BIO For: 2 July By Investing.com - Investing.com Nigeria
David Lazar trims KALA BIO (KALA) stake to 3.9% with 719,404 shares - Stock Titan
Price to earnings forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
KALA BIO Inc. (KALA) Holds Near Support After Slight Decline: Key Levels in FocusVanna Flow - dars.gov.et
[EFFECT] KALA BIO, Inc. SEC Filing - Stock Titan
Enterprise value to EBIT forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Enterprise value to EBITDA forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Price to book forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Enterprise value to revenue forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
KALA BIO Surges on Heavy Volume: Biotech Stock Testing Key Resistance LevelsAAII Bearish - DonanımHaber
KALA BIO StockLong-term eye-disease strategy in focus - AD HOC NEWS
KALA BIO Inc (KALA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
KALA BIO Inc (KALA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KALA BIO Inc (KALA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
KALA BIO Inc (KALA) Valuation: PE, PB & Fair Value Analysis - TradingKey
KALA BIO Inc. Surges 6.5% as Biotech Momentum Builds: Testing Key Resistance at $2.76Resistance Breakout Stocks - newsline.com
KALA Q4 2025 Earnings: Narrowed Loss Drives 6.5% Stock GainQuarterly Earnings Report - newsline.com
KALA BIO (NASDAQ: KALA) registers $350M shelf; 1-for-50 reverse split recorded - Stock Titan
KALA BIO Inc. (KALA) Holds Steady Near Support Amid Minimal Price MovementMoving Average Ribbon - newsline.com
KALA BIO (KALA) Holds Steady Near $2.39 Amid Tight Trading RangeUpthrust Pattern - newsline.com
KALA BIO Surges 11%: Approaching Key Resistance at $2.40Wave Truncation - newsline.com
KALA Q4 2025 Earnings: Narrower Loss Beats Expectations Amid Operational ProgressQuarterly Earnings - dars.gov.et
KALA BIO INC (KALA) Stock Chart - ChartMill
KALA Stock Price, Quote & Chart | KALA BIO INC (NASDAQ:KALA) - ChartMill
KALA BIO Q4 2025 Earnings: Wider-Than-Expected Loss but Narrower EPS Surprise Drives Mixed Sentiment - dars.gov.et
KALAKala Bio Inc Stock Price and Quote - Finviz
Net margin % of KALA BIO, Inc. – LSX:A4243T - TradingView
KALA BIO Shares Slide Over 6% Amid Light Trading and Sector PressureATR Stop - dars.gov.et
KALA BIO (KALA) Smashes Q4 2025 Views with $-33.50 EPSNegative Surprise Momentum - thelegaladvocate.com
KALA BIO (KALA) Q4 2025 Earnings Beat: Revenue $N/A, EPS $-33.50Free Cash Flow Trends - newsline.com
Kala Bio (FRA:27F) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2026) - GuruFocus
Red Light Holland Corp (OP: TRUFF - FinancialContent
KALA stock hits record low – firm announces reverse split after shares fail to surpass the $1 mark - MSN
칼라 파마슈티컬스 (KALA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.84%
0.86%
자본화:
|
볼륨(24시간):